



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 16679/S-108
NDA 19367/S-030

SUPPLEMENT APPROVAL

Baxter Healthcare Corporation
Attention: Nikhita Pilla
Sr. Associate, Regulatory Affairs
32650 N Wilson Road
Mail Stop WG1-3
Round Lake, IL 60073

Dear Ms. Pilla

Please refer to your Supplemental New Drug Applications (sNDA) dated and received April 25, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

<u>Application</u>	<u>Product Name</u>
16679/S-108	Lactated Ringer's and 5% Dextrose Injection, USP in Plastic Container
19367/S-030	Potassium Chloride in 5% Dextrose and Lactated Ringer's Injection, USP in Plastic Container

These Prior Approval supplemental new drug applications provide for the following changes to the listed sections of the prescribing information:

- Description - add that Dextrose is derived from corn
- Warnings – remove caution for those allergic to corn or corn products
- Precautions - add information regarding air embolism; remove subsections containing no data; reorganize subsections; remove pregnancy category;
- Update Pregnancy and Labor and Delivery sections
- Adverse Reactions – remove Class Reactions subsection heading
- Dosage and Administration – add reminder to discard unused product after opening; add recommendation to monitor serum glucose concentrations in pediatric patients; add recommendation to use final filter and inspect solution
- Directions for Use – add instruction to visually inspect container

APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Heather Buck, Regulatory Project Manager, at (301) 796-1413.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling